Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Wellnara** is a continuous oral fixed-dose hormone replacement therapy containing estradiol 1 mg, supplied as estradiol hemihydrate, and levonorgestrel 0.04 mg per film-coated tablet. It is used to treat estrogen-deficiency symptoms in postmenopausal women; estradiol replaces declining endogenous estrogen activity, while the progestin levonorgestrel provides progestogenic opposition to estrogenic stimulation of the endometrium in women with a uterus. Bayer has also conducted post-marketing surveillance of Wellnara in Japan in postmenopausal osteoporosis. ([gelbe-liste.de](https://www.gelbe-liste.de/produkte/Wellnara-1-mg-0-04-mg-Filmtabletten_501079/fachinformation))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + levonorgestrel (Bayer).